{"transactions":[{"id":2480636,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":132665,"kind":"person","name":"Zarrabian Saiid","position":1,"cik":"0001495521","reported_name":"Zarrabian Saiid","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Strategic Partnerships"}}],"security":"Common Stock","published_at":"2021-12-08T21:09:27.000Z","date":"2021-12-07","kind":"purchase","acquired":true,"shares":38109,"price":0.6376,"value":24298.2984,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.63115 to $0.6415 per share, inclusive. The reporting person undertakes to provide to Kintara Therapeutics, Inc., any security holder of Kintara Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On May 8, 2019, Kintara Therapeutics, Inc. effected a 1-for-10 reverse stock split of its common stock (the \"Reverse Stock Split\"). The number of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split."}],"balance_after":55500,"source":{"system":"sec-edgar","filing":"0000899243-21-047320","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000089924321047320/doc4.xml","form_type":"4"}},{"id":2480635,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":132665,"kind":"person","name":"Zarrabian Saiid","position":1,"cik":"0001495521","reported_name":"Zarrabian Saiid","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Strategic Partnerships"}}],"security":"Common Stock","published_at":"2021-12-08T21:09:27.000Z","date":"2021-12-06","kind":"purchase","acquired":true,"shares":11891,"price":0.5902,"value":7018.0682,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.59 to $0.5902 per share, inclusive. The reporting person undertakes to provide to Kintara Therapeutics, Inc., any security holder of Kintara Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On May 8, 2019, Kintara Therapeutics, Inc. effected a 1-for-10 reverse stock split of its common stock (the \"Reverse Stock Split\"). The number of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split."}],"balance_after":17391,"source":{"system":"sec-edgar","filing":"0000899243-21-047320","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000089924321047320/doc4.xml","form_type":"4"}},{"id":3028419,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":132665,"kind":"person","name":"Zarrabian Saiid","position":1,"cik":"0001495521","reported_name":"Zarrabian Saiid","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Options (Right to Buy)","published_at":"2020-09-18T01:07:19.000Z","date":"2020-09-15","kind":"grant","acquired":true,"shares":2715004,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued employment, 1/6th of the options vest on March 15, 2021, with the remaining shares vesting in equal monthly installments over a period of 30 months commencing on April 15, 2021."}],"balance_after":2715004,"derivative":{"exercise_price":1.7,"expiration_date":"2030-09-15","underlying":"Common Stock","underlying_shares":2715004},"source":{"system":"sec-edgar","filing":"0000905718-20-000969","document":"kintara_fm4sep152020.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000090571820000969/kintara_fm4sep152020.xml","form_type":"4"}},{"id":3096573,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":132665,"kind":"person","name":"Zarrabian Saiid","position":1,"cik":"0001495521","reported_name":"Zarrabian Saiid","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Options (Right to Buy)","published_at":"2020-06-30T20:08:30.000Z","date":"2020-06-26","kind":"grant","acquired":true,"shares":241438,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 5, 2019, the reporting person received options to purchase 241,438 shares which were subject to stockholder approval of the increase in the number of shares authorized for issuance under the DelMar Pharmaceuticals, Inc. 2017 Omnibus Equity Incentive Plan, as amended, at the 2020 Annual Meeting of Stockholders. Stockholder approval of the increase was obtained on June 26, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/6th of the options vested on March 5, 2020 with the remaining shares vesting in equal monthly installments over a period of 30 months commencing on April 5, 2020."}],"balance_after":457650,"derivative":{"exercise_price":0.61,"expiration_date":"2029-09-05","underlying":"Common Stock","underlying_shares":241438},"source":{"system":"sec-edgar","filing":"0001213900-20-016303","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000121390020016303/ownership.xml","form_type":"4"}},{"id":3419571,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":132665,"kind":"person","name":"Zarrabian Saiid","position":1,"cik":"0001495521","reported_name":"Zarrabian Saiid","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Options (Right to Buy)","published_at":"2019-09-09T20:39:49.000Z","date":"2019-09-05","kind":"grant","acquired":true,"shares":216212,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/6th of the options vest on March 5, 2020 with the remaining shares vesting in equal monthly installments over a period of 30 months commencing on April 5, 2020."}],"balance_after":216212,"derivative":{"exercise_price":0.61,"expiration_date":"2029-09-05","underlying":"Common Stock","underlying_shares":216212},"source":{"system":"sec-edgar","filing":"0000905718-19-000763","document":"delmarph_fm4sept52019.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000090571819000763/delmarph_fm4sept52019.xml","form_type":"4"}},{"id":3419570,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":132665,"kind":"person","name":"Zarrabian Saiid","position":1,"cik":"0001495521","reported_name":"Zarrabian Saiid","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Options (Right to Buy)","published_at":"2019-09-09T20:39:49.000Z","date":"2019-09-05","kind":"grant","acquired":true,"shares":241438,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to stockholder approval of the increase in the number of shares authorized for issuance under the DelMar Pharmaceuticals, Inc. 2017 Omnibus Equity Incentive Plan, as amended, at the next annual meeting, 1/6th of the options vest on March 5, 2020 with the remaining shares vesting in equal monthly installments over a period of 30 months commencing on April 5, 2020."}],"balance_after":241438,"derivative":{"exercise_price":0.61,"expiration_date":"2029-09-05","underlying":"Common Stock","underlying_shares":241438},"source":{"system":"sec-edgar","filing":"0000905718-19-000763","document":"delmarph_fm4sept52019.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000090571819000763/delmarph_fm4sept52019.xml","form_type":"4"}},{"id":3544353,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":132665,"kind":"person","name":"Zarrabian Saiid","position":1,"cik":"0001495521","reported_name":"Zarrabian Saiid","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Performance Stock Units","published_at":"2019-05-01T22:34:10.000Z","date":"2019-04-30","kind":"disposition_to_issuer","acquired":false,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance stock unit represents the right to receive one share of common stock, to vest upon achievement of specified targets related to the Company's financial performance. Such performance stock units were unvested."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each performance stock unit represents the right to receive one share of common stock, to vest upon achievement of specified targets related to the Company's financial performance. Such performance stock units were unvested."}],"balance_after":0,"derivative":{"expiration_date":"2022-07-07","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001213900-19-007628","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000121390019007628/ownership.xml","form_type":"4"}},{"id":3922060,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":132665,"kind":"person","name":"Zarrabian Saiid","position":1,"cik":"0001495521","reported_name":"Zarrabian Saiid","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2018-05-22T10:25:25.000Z","date":"2018-05-21","kind":"grant","acquired":true,"shares":836465,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/6th of the options vest on November 21, 2018 with the remaining shares vesting in equal monthly installments over a period of 30 months commencing on December 21, 2018."}],"balance_after":836465,"derivative":{"exercise_price":0.9825,"expiration_date":"2028-05-21","underlying":"Common Stock","underlying_shares":836465},"source":{"system":"sec-edgar","filing":"0001213900-18-006696","document":"f4052118zarrabian_delmar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000121390018006696/f4052118zarrabian_delmar.xml","form_type":"4"}},{"id":4160503,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":132665,"kind":"person","name":"Zarrabian Saiid","position":1,"cik":"0001495521","reported_name":"Zarrabian Saiid","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CEO"}}],"security":"Common Stock","published_at":"2017-11-16T21:30:59.000Z","date":"2017-11-14","kind":"purchase","acquired":true,"shares":5900,"price":0.84,"value":4956.0,"ownership":{"direct":false,"nature":"By Child"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $0.8298 to $0.84. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":5900,"source":{"system":"sec-edgar","filing":"0001213900-17-012230","document":"f4111417zarrabian_delmar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000121390017012230/f4111417zarrabian_delmar.xml","form_type":"4"}},{"id":4160502,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":132665,"kind":"person","name":"Zarrabian Saiid","position":1,"cik":"0001495521","reported_name":"Zarrabian Saiid","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CEO"}}],"security":"Common Stock","published_at":"2017-11-16T21:30:59.000Z","date":"2017-11-14","kind":"purchase","acquired":true,"shares":55000,"price":0.82,"value":45100.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $0.8015 to $0.8385. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":55000,"source":{"system":"sec-edgar","filing":"0001213900-17-012230","document":"f4111417zarrabian_delmar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000121390017012230/f4111417zarrabian_delmar.xml","form_type":"4"}},{"id":4170149,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":132665,"kind":"person","name":"Zarrabian Saiid","position":1,"cik":"0001495521","reported_name":"Zarrabian Saiid","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CEO"}}],"security":"Options (Right to Buy)","published_at":"2017-11-08T01:10:47.000Z","date":"2017-11-03","kind":"grant","acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the first anniversary of the date of grant."}],"balance_after":120000,"derivative":{"exercise_price":0.87,"expiration_date":"2027-11-03","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001213900-17-011531","document":"f4110317zarrabian_delmar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000121390017011531/f4110317zarrabian_delmar.xml","form_type":"4"}},{"id":4259076,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":132665,"kind":"person","name":"Zarrabian Saiid","position":1,"cik":"0001495521","reported_name":"Zarrabian Saiid","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Performance Stock Units","published_at":"2017-07-12T01:41:07.000Z","date":"2017-07-07","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Subject to stockholder approval of the Company's 2017 Omnibus Equity Incentive Plan at the Company's annual meeting, each performance stock unit represents the right to receive one share of common stock upon vesting of the unit based on targets related to the Company's financial performance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to stockholder approval of the Company's 2017 Omnibus Equity Incentive Plan at the Company's annual meeting, each performance stock unit represents the right to receive one share of common stock upon vesting of the unit based on targets related to the Company's financial performance."}],"balance_after":200000,"derivative":{"expiration_date":"2022-07-07","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0000905718-17-000668","document":"zarrabian_form4jul72017.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000090571817000668/zarrabian_form4jul72017.xml","form_type":"4"}},{"id":4259075,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":132665,"kind":"person","name":"Zarrabian Saiid","position":1,"cik":"0001495521","reported_name":"Zarrabian Saiid","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options (Right to Buy)","published_at":"2017-07-12T01:41:07.000Z","date":"2017-07-07","kind":"grant","acquired":true,"shares":36000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"12,000 options vest on June 30, 2018, and 3,000 options vest each three months thereafter starting September 30, 2018."}],"balance_after":36000,"derivative":{"exercise_price":2.11,"exercise_date":"2020-07-07","expiration_date":"2027-07-07","underlying":"Common Stock","underlying_shares":36000},"source":{"system":"sec-edgar","filing":"0000905718-17-000668","document":"zarrabian_form4jul72017.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000090571817000668/zarrabian_form4jul72017.xml","form_type":"4"}}]}